Shin Eunah, Chung Woung Youn, Yang Woo Ick, Park Cheong Soo, Hong Soon Won
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
J Korean Med Sci. 2005 Feb;20(1):98-104. doi: 10.3346/jkms.2005.20.1.98.
Recently, the rearrangement of RET proto-oncogene has been reported to be the most common genetic change in papillary thyroid carcinoma (PTC). However, its prevalence has been reported variably and its relation to clinical outcome has been controversial. The characteristic nuclear features of PTC usually render the diagnosis, but problem arises with equivocal cytologic features that are present focally. Although there remains some controversy, CK19 has been reported to be a useful ancillary tool for diagnosis of PTC. To evaluate the expression rate of RET/PTC rearrangement and CK19 in PTCs in a Korean population, we studied 115 papillary thyroid carcinomas in 3 mm-core tissue microarray based immunohistochemical analysis. The prevalence of Ret protein expression was 62.6% and the CK19 immunoreactivity was 80.9%. There was no statistically significant association between the Ret positivity and CK19 immunoreactivity, although the percent agreement of the two was relatively high. The clinicopathological variables did not correlate with the expression of Ret. In conclusion, the prevalence of Ret protein expression and its clinicopathological implications in a Korean population are not much different from those reported in previous studies. However, its detection via immunohistochemistry can be a useful diagnostic tool for diagnosing papillary thyroid carcinoma in conjunction with CK19.
最近，有报道称RET原癌基因重排是甲状腺乳头状癌（PTC）中最常见的基因改变。然而，其发生率的报道各不相同，并且其与临床结局的关系也存在争议。PTC的特征性核特征通常有助于诊断，但局灶性存在的模糊细胞学特征会引发问题。尽管仍存在一些争议，但CK19已被报道是诊断PTC的一种有用辅助工具。为了评估韩国人群中PTC中RET/PTC重排和CK19的表达率，我们基于免疫组织化学分析，在3毫米芯组织微阵列中研究了115例甲状腺乳头状癌。Ret蛋白表达的发生率为62.6%，CK19免疫反应性为80.9%。尽管两者的一致性百分比相对较高，但Ret阳性与CK19免疫反应性之间没有统计学上的显著关联。临床病理变量与Ret的表达无关。总之，韩国人群中Ret蛋白表达的发生率及其临床病理意义与先前研究报道的差异不大。然而，通过免疫组织化学检测Ret结合CK19可成为诊断甲状腺乳头状癌的有用诊断工具。
